Quantitative assessment of minimal residual disease for monitoring of paediatric patients with relapsed/refractory anaplastic large-cell lymphoma treated with brentuximab vedotin: A case series

Br J Haematol. 2024 Jan;204(1):352-355. doi: 10.1111/bjh.19151. Epub 2023 Oct 11.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Brentuximab Vedotin
  • Child
  • Hodgkin Disease* / pathology
  • Humans
  • Immunoconjugates* / therapeutic use
  • Lymphoma, Large-Cell, Anaplastic* / diagnosis
  • Lymphoma, Large-Cell, Anaplastic* / drug therapy
  • Neoplasm Recurrence, Local
  • Neoplasm, Residual

Substances

  • Brentuximab Vedotin
  • Immunoconjugates